Clinical trials for patients with Hodgkin Lymphoma or non-Hodgkin Lymphoma. This group of cancer affects a type of white blood cell that plays an important role in the immune system
If you would like to be considered for a clinical trial you will require a referral from your current treating team.
Visit the Joining a Clinical Trial page for referral information.
For more information on clinical trials, get in contact with our cancer clinical trials enquiry coordinator.
Business hours, Mon to Friday between 9am - 2pm
Cancer type
B-cell non-Hodgkin’s lymphomas – follicular lymphoma (FL), marginal zone lymphoma (MZL), mantle cell lymphoma (MCL), diffuse large B cell lymphoma (DLBCL), primary mediastinal B cell lymphoma (PMBCL) including patients who show Richter’s transformation.
Status
Open and recruiting
Phase
One: A phase one clinical trial tests new treatments sometimes for the first time in humans, usually in a small group of patients. The aim of a phase one is to test the safety of the new treatment and find the best dose to give patients.
Brief summary
The purpose of this clinical trial is to find the best dose of a new treatment RO7082859, given alone or in combination with Obinituzumab and how effective it is on certain cancers. The treatment RO7082859 is a T-cell bispecific antibody which works by activating or supporting the body’s own immune system to identify and kill cancer cells. Obinituzaumab is an antibody that targets the lymphoma cells. The drugs are given intravenously .
Who can participate
Patients who:
Clinical trials can have restrictive criteria of who can and can’t participate, talk to your doctor if you are interested in this clinical trial.
Cancer type
B-cell non-Hodgkin’s lymphoma - Follicular lymphoma (FL), marginal zone lymphoma, mantle cell lymphoma, diffuse large B-cell lymphoma (DLBCL), primary mediastinal B-cell lymphoma (PMBCL), transformed follicular lymphoma and Richter’s transformation.
Status
Open and recruiting
Phase
One: A phase one clinical trial tests new treatments sometimes for the first time in humans, usually in a small group of patients. The aim of a phase one is to test the safety of the new treatment and find the best dose to give patients.
Brief summary
The purpose of this clinical trial is to best dose of a new treatment RO70227166 given with either Obinituzumab or RO7082859 and how effective it is on certain cancers. Treatment is given intravenously (through a needle in your arm).
Who can participate
Patients who:
Clinical trials can have restrictive criteria of who can and can’t participate, talk to your doctor if you are interested in this clinical trial.
Cancer Type
Aggressive B-cell non-Hodgkin lymphoma
Status
Open and recruiting
Phase
Three: A phase three clinical trial follows a phase two, in a larger group of patients with specific cancer types. The aim of a phase three is to compare the new treatment to what is available for that cancer type.
Brief summary
A clinical trial to compare the safety and effectiveness of treatment Tisagenlecleucel to the treatment standardly given to patients with aggressive B-cell non-Hodgkin lymphoma. Patients will be given one of the following:
Who can participate
Patients who:
Clinical trials can have restrictive criteria of who can and can’t participate, talk to your doctor if you are interested in this clinical trial.
Cancer Type
Hodgkin Lymphoma
Status
Open and recruiting
Phase
Two: A phase two clinical trial follows a phase one, in a large group of patients with selected cancer types. The aim of a phase two is to find out if the new treatment is effective in these cancer types.
Brief summary
A study to assess if Pembrolizumab is an effective treatment in Hodgkin lymphoma patients when they are unable to receive standard chemotherapy. Patients will be given Pembrolizumab intravenously (through a needle in your arm) every 3 weeks.
Who can participate
Patients who:
Clinical trials can have restrictive criteria of who can and can’t participate, talk to your doctor if you are interested in this clinical trial.
Cancer Type
Hodgkin lymphoma
Status
Open and recruiting
Phase
One / two: A phase one / two clinical trial combines a phase one and two. The phase one tests new treatments sometimes for the first time in humans, usually in a small group of patients. The phase two part tests the new treatment in a larger group of patients with selected cancer types. The aim of a phase one / two is to find the best dose of the new treatment and see if it works against the cancer.
Brief summary
A clinical trial which uses the treatment Brentuximab Vedotin given with donor lymphocytes (type of white blood cell, found in the immune system and collected from the same donor who provided the cells for the original transplant) in patients with Hodgkin’s Lymphoma that has persisted after an allogeneic stem cell transplant. The results of PET scans are used to determine when to commence the brentuximab.
Who can participate
Patients who:
Clinical trials can have restrictive criteria of who can and can’t participate, talk to your doctor if you are interested in this clinical trial.
Cancer Type
Follicular Lymphoma
Status
Open and recruiting
Phase
One / two: A phase one / two clinical trial combines a phase one and two. The phase one tests new treatments sometimes for the first time in humans, usually in a small group of patients. The phase two part tests the new treatment in a larger group of patients with selected cancer types. The aim of a phase one / two is to find the best dose of the new treatment and see if it works against the cancer.
Brief summary
A clinical trial to find the best dose of Venetoclax ,when combined with lenolidomide and Obinituzumab in patients with Follicular Lymphoma and to find out how effective this combination of treatment is. Lenalidomide and Venetoclax are taken orally, Obinituzumab is given intravenously (through a needle in your arm) together in cycles, 12 cycles in total.
Who can participate
Patients who:
Clinical trials can have restrictive criteria of who can and can’t participate, talk to your doctor if you are interested in this clinical trial.